BMAL1 and disease of the tendon: Additionally, we developed an injectable biomaterial based on Nb2C@CeO2 with Schottky heterojunctions capable of regulating the expression of Bmal1 to modulate circadian rhythms and verified their effectiveness in treating tendinopathy.